search
Back to results

Prevention of Diseases Induced by Chlamydia Trachomatis (i-PREDICT)

Primary Purpose

Genital Chlamydia Trachomatis Infection

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Testing for Ct infection immediately
Testing for Ct infection at the end of the study
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Genital Chlamydia Trachomatis Infection focused on measuring Chlamydia trachomatis, Pelvic inflammatory disease

Eligibility Criteria

18 Years - 24 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • female students visiting the preventive medical centers of universities or the Ct screening test centers who participate in the study;
  • participate in or will participate in the "i-Share" cohort;
  • aged between 18 to 24 years,
  • had prior sexual relations,
  • written informed consent signed,
  • affiliated to the social security bodies.

Exclusion Criteria:

  • Known pregnancy.

Sites / Locations

  • Université de Versailles Saint Quentin

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Intervention group

Control group

Arm Description

Testing for Ct infection immediately Participants will perform self-taken vaginal samples. The positive results for Ct will be examined and treated and their partner will also be informed to do so.

Testing for Ct infection at the end of the study

Outcomes

Primary Outcome Measures

Cumulative incidence
Cumulative incidence of first PID

Secondary Outcome Measures

Incidence of first Ct infection
Incidence of first Ct infection for negative participants at baseline
Duration of Ct infection
Proportion of Ct infection progressing to PID
Time of Ct infection progressing to PID
Proportion of spontaneous resolution of Ct infections
Proportion of spontaneous resolution of Ct infections
Incidence of reinfections
Incidence of reinfections

Full Information

First Posted
September 14, 2016
Last Updated
March 15, 2023
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
National Reference Center (NRC) for Chlamydia infections, UMR1181
search

1. Study Identification

Unique Protocol Identification Number
NCT02904811
Brief Title
Prevention of Diseases Induced by Chlamydia Trachomatis
Acronym
i-PREDICT
Official Title
Prevention of Diseases Induced by Chlamydia Trachomatis
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Completed
Study Start Date
January 10, 2017 (Actual)
Primary Completion Date
November 15, 2022 (Actual)
Study Completion Date
November 15, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
National Reference Center (NRC) for Chlamydia infections, UMR1181

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The main objective of the study is to determine whether early screening and treating young women (<25 years of age) for genital Chlamydia Trachomatis (Ct) infection reduces the cumulative incidence of pelvic inflammatory disease (PID) over 24 months. As secondary objectives, the study aims To determine the baseline prevalence and the incidence of Ct infection; To improve knowledge on natural history of Ct infection in young women such as the rate and timing of progression to PID (at the beginning of the infection, at the end, throughout the course of infection), as well as the incidence of reinfections with Ct; To investigate the relation between host immuno-genetic factors and the clearance, persistence and development of late complications (PID) as an explanation for the inter-individual heterogeneity in the susceptibility to and course of Ct infection.
Detailed Description
In this research project, the study aims to assess a screening strategy (early screening and treatment of Ct genital infection in young women to prevent complications) that may be implemented in the future if proved efficient 7 centers are involved in the enrollment (university health services), and 4 centers will participate in the study within the frame of the follow-up and final visit (hospital gynaecology departments). Participants included will have to perform 4 self-taken vaginal samples linked to four online corresponding questionnaires, at different timeframes 6-month apart to each other (M0, M6, M12, M18). The first sampling (M0) will be performed at the university health service, this self-taken sampling could also be performed at home later in case of menstruation; the others (M6, M12, M18) will be performed at home (or at the university if problem of sampling kits receiving at home). Participants will be randomly assigned to one of the two following arms: in the non-intervention arm, participants will follow current guidelines of Ct screening (i.e. opportunistic screening only in STI clinics for women aged less than 25 years old), and their samples will be tested for Ct at M18 by the NRC; in the intervention arm, analyses for Ct will be carried out immediately by the NRC. A final visit with a hospital gynecologist is planned for all participants between M18 and M24 and aims at providing an extensive clinical examination to seek for potential signs of pelvic inflammatory disease and to treat participants if needed. Based on all data collected on the electronic platform through questionnaires from the different visits, independent experts blinded on chlamydia status will assess PID status of all participants (no PID, probable PID, confirmed PID). The duration of enrollment is planned for 36 months. The duration of follow-up for each patient is 18 months to 24 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Genital Chlamydia Trachomatis Infection
Keywords
Chlamydia trachomatis, Pelvic inflammatory disease

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
1092 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention group
Arm Type
Experimental
Arm Description
Testing for Ct infection immediately Participants will perform self-taken vaginal samples. The positive results for Ct will be examined and treated and their partner will also be informed to do so.
Arm Title
Control group
Arm Type
Experimental
Arm Description
Testing for Ct infection at the end of the study
Intervention Type
Other
Intervention Name(s)
Testing for Ct infection immediately
Intervention Description
Self-taken vaginal samples will be immediately tested for Ct infection at the National Reference Centre (CNR) at University of Bordeaux, using a commercially available CE marketed real-time PCR assay.
Intervention Type
Other
Intervention Name(s)
Testing for Ct infection at the end of the study
Intervention Description
Self-taken vaginal samples will be tested for Ct infection at the end of the study (M18).
Primary Outcome Measure Information:
Title
Cumulative incidence
Description
Cumulative incidence of first PID
Time Frame
At 24 months
Secondary Outcome Measure Information:
Title
Incidence of first Ct infection
Description
Incidence of first Ct infection for negative participants at baseline
Time Frame
Up to 24 months
Title
Duration of Ct infection
Time Frame
Up to 24 months
Title
Proportion of Ct infection progressing to PID
Time Frame
Up to 24 months
Title
Time of Ct infection progressing to PID
Time Frame
Up to 24 months
Title
Proportion of spontaneous resolution of Ct infections
Description
Proportion of spontaneous resolution of Ct infections
Time Frame
Up to 24 months
Title
Incidence of reinfections
Description
Incidence of reinfections
Time Frame
Up to 24 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
24 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: female students visiting the preventive medical centers of universities or the Ct screening test centers who participate in the study; participate in or will participate in the "i-Share" cohort; aged between 18 to 24 years, had prior sexual relations, written informed consent signed, affiliated to the social security bodies. Exclusion Criteria: Known pregnancy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Elisabeth Delarocque-Astagneau, MD
Organizational Affiliation
Université de Versailles Saint Quentin
Official's Role
Study Chair
Facility Information:
Facility Name
Université de Versailles Saint Quentin
City
Versailles
State/Province
Saint-Quentin-en-Yvelines
ZIP/Postal Code
78000
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
29132441
Citation
Tamarelle J, Thiebaut ACM, Sabin B, Bebear C, Judlin P, Fauconnier A, Rahib D, Meaude-Roufai L, Ravel J, Morre SA, de Barbeyrac B, Delarocque-Astagneau E; i-Predict study group. Early screening for Chlamydia trachomatis in young women for primary prevention of pelvic inflammatory disease (i-Predict): study protocol for a randomised controlled trial. Trials. 2017 Nov 13;18(1):534. doi: 10.1186/s13063-017-2211-1.
Results Reference
derived

Learn more about this trial

Prevention of Diseases Induced by Chlamydia Trachomatis

We'll reach out to this number within 24 hrs